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A B S T R A C T
Hashimoto’s encephalopathy is an under-recognized and rare disease that presents a diagnostic
conundrum since many features are suggestive of infectious etiologies and yet treatment is
immunosuppressive medications. We describe a case of a male with a history of recurrent seizures
who presented with a subacute onset of confusion, persistent leukocytosis and fever while on
immunosuppressant therapy, whose response to high dose steroids was incomplete and who achieved a
complete remission of all symptoms when plasmapheresis was initiated. A negative cerebrospinal ﬂuid
(CSF) and serum microbiological testing in a patient with an abnormal EEG, increased CSF protein, and
elevated thyroid antibodies should prompt consideration of Hashimoto’s encephalopathy. If after
treating with high dose steroids, there is a sub-optimal clinical response, plasmapheresis should be
considered.
 2011 Published by Elsevier Ltd on behalf of British Epilepsy Association.
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Hashimoto’s encephalopathy (HE), a rare but treatable disease,
has a prevalence of only 2.1 cases per 100,000 persons1; this along
with the variability in presentation makes it a very challenging
diagnosis. The following case report illustrates the responsiveness
of this disease in a severely afﬂicted patient who failed to respond
to steroids but had a prompt and complete response to
plasmapheresis. We then review the literature regarding the
diagnosis and treatment of HE.
2. Case report
A 45-year-old male found wandering outside his apartment
building at night in freezing temperature wearing only his
underwear was brought to the hospital by ambulance and
appeared confused. The patient’s family later conﬁrmed that for
one week prior, he had severe headaches, nausea and vomiting,
slurred speech, and confusion. About 15 months previously, he had
presented to another hospital with new onset seizures, was
encephalopathic and was found to be hypothyroid. Extensive
work-up had ruled out infectious, toxic, metabolic, malignant and
paraneoplastic etiologies and Creutzfeldt–Jakob disease. His
thyroid-stimulating hormone (TSH) levels ranged from 4.56 to
8.08 IU/ml. Anti-thyroid peroxidase antibodies (TPOAb) and anti-* Corresponding author at: Department of Medicine, Greater Baltimore Medical
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>1000 IU/ml with normal levels <35 IU/ml, TgAb >3000 IU/ml
with normal levels <20 IU/ml).
Initial treatment at the outside hospital with a combination of
two anticonvulsants was ineffective. However, after 3 days of
prednisone (60 mg/d) his seizures resolved. Unfortunately,
attempts to taper steroids resulted in recurrent seizures despite
concurrent treatment with levetiracetam and topiramate. Repeat-
edly, after increasing the prednisone to 60 mg/d, he would quickly
improve with resolution of the seizures and delirium. He was
ﬁnally tapered off steroids 6 months later and continued to
function well, working daily, and had no seizure activity on
mycophenolate mofetil, levetiracetam, topiramate and levothyr-
oxine for about 9 months until this admission.
At our hospital, he was started on broad-spectrum antibiotics
for possible infectious meningitis or encephalitis. Lumbar
puncture revealed elevated CSF protein levels (221 mg/dl)
without pleocytosis. His records from the hospital where he
had been treated for HE’s disease were reviewed and methyl-
prednisolone was initiated at 60 mg/d IV every 12 h for 2 doses
then every 8 h on the second and third days. Despite steroids, the
patient’s condition deteriorated with worsening disorientation,
intermittent severe agitation, high fevers, and a persistent
leukocytosis. CSF cultures were negative for common bacteria,
acid-fast bacilli, fungi, cryptococcus antigen, herpes DNA
polymerase chain reaction (PCR) and anti-neuronal nuclear
antibody type 1. Blood and urine cultures were negative and
toxicology screening was unrevealing. His TSH was 32.5 IU/ml,
TPOAb and TgAb levels were >6500 IU/ml (normally <60 IU/ml)
and >25,000 IU/ml (normally <60 IU/ml) respectively. Electro-
encephalogram (EEG) showed diffuse slowing and disorganiza-Epilepsy Association.
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resonance imaging (MRI) revealed non-enhancing bilateral
hemispheric white matter T2/FLAIR hyperintensity.
Methylprednisolone was then increased to 1 g/d IV for 5 days,
and the patient exhibited a partial response with less agitation and
improved orientation, but still was not close to baseline.
Plasmapheresis was begun with a return to a normal mental
status within the ﬁrst 24 h. A total of 5 sessions were given and he
was discharged home on prednisone (50 mg daily), levothyroxine,
levetiracetam and topiramate. Gradually, he was tapered off
prednisone and is symptom-free for over one year of follow-up on
mycophenolate mofetil, levetiracetam, topiramate and levothyr-
oxine.
3. Discussion
Since HE was ﬁrst described by Brain et al. in 1966,2 there have
been fewer than 200 cases reported. One of the larger case reviews3
found a female to male ratio of 4:1 with an average age of onset of
44 years. Among these 85 patients, 23 (27%) had stroke like signs,
56 (66%) had seizures, and 32 (38%) had psychosis. Fever and
leukocytosis rarely occurred. A Medline search from 1967 and
January 2011 showed only 4 cases that presented with fever with
or without leukocytosis associated with HE, and 3 of 4 cases
responded to steroids treatment.4–7
HE may present with unexplained episodes of relapsing
myoclonus, generalized seizures, focal neurological deﬁcits or
psychiatric disorders and should have at least three of the
following conditions: an abnormal EEG, elevated thyroid anti-
bodies, elevated CSF protein and/or oligoclonal bands, an excellent
response to steroids and a nonspeciﬁc but abnormal cerebral MRI.8
The differential diagnosis includes viral encephalitis, Creutzfeldt–
Jakob disease, central nervous system vasculitis, and paraneo-
plastic autoimmune encephalopathies.
HE is also known as ‘‘steroid-responsive encephalopathy
associated with thyroid autoimmunity’’. It is different from
neurologic complications of hypothyroidism in that the addition
of thyroxine will not cure the patient and the disease will
demonstrate progression of neurologic symptoms without signiﬁ-
cant immunosuppressive therapy.
The pathogenesis of HE remains unclear. Autoimmune vasculi-
tis is purported to play a role and evidence for this is perivascular
lymphocytic inﬁltration seen in ﬁve of seven of the pathology
reports from brain tissue samples.3,9 Other hypotheses are that the
cerebrospinal ﬂuid thyroid autoantibodies, either synthesized
intrathecally or systemically derived and crossing the damaged
blood–brain barrier, may react with a putative intracranial antigen
and form localized immune complexes.10–12 The improvement of
the symptoms with steroids or plasmapheresis is indirect evidence
of the role of auto-immunopathology.13–16
Elevated titers of anti-thyroid antibodies (especially TPOAb) are
considered to be a hallmark of HE. Some authors contend that
antibody levels have little causality and have found no relationship
to disease severity,3,17 as was true in our case. This patient’s TPOAb
and TgAb levels did not change and remained high even when he
was symptom-free (TPOAb >1000 IU/ml with normal levels
<35 IU/ml, TgAb >3000 IU/ml with normal levels <20 IU/ml 10
months after he ﬁrst presented). However, with these persistently
high levels, he did relapse 15 months later. This also has been
found to be the case where patients with ﬂuctuation in their
symptoms had either persistently high or highly variable levels of
antithyroid antibodies. Similarly, patients who failed to respond to
steroids also more often had persistent elevation in antithyroid
antibodies13,15,18; thus, normalization of the serum antithyroid
antibodies normalize may be a good prognostic sign with a higherchance of successful weaning of steroids and remaining symptom-
free with treatment.4,13–16,18
In summary, although persistent elevated anti-TPOAb levels do
not correlate with disease severity, it seems that they do appear to be
predictive of relapses, a prolonged disease course, less responsive to
steroids, and a worse prognosis. The authors suggested that serial
antithyroid antibody levels could be used both to predict the disease
course as well as response to therapy. Patients with high anti-TPOAb
levels often require a very slow steroid tapering, and consideration
should be given to combining steroids with other immunosuppres-
sive agents to avoid recurrence of HE.18
Treatment of HE consists of immunosuppressive agents and/or
thyroid hormone replacement, as well as anticonvulsant drugs for
seizures. Initial treatment usually is prednisone, which is tapered
within weeks to months according to clinical response. Even with
maintenance steroids or immunosuppressant therapy, relapses
are not rare. With recurrence of HE, an increased steroid dose or
pulse dosing may be needed,15,18 and patients may evolve with
time to a steroid-resistant state. Given the immunosuppression of
these patients, the exclusion of an infectious cause is critically
important.
Immune modulation with serial plasmapheresis may be a
more effective strategy than additional immunosuppression in
those who have relapsed or who have shown steroid resistance
with signiﬁcant improvement usually seen after the ﬁrst
treatment.13,14,19
Over time, the course of this disease is generally either
remitting-replasing with acute/subacute seizures or stroke-like
episodes, or is progressive with an insidious onset of dementia or
psychosis that steadily worsens.15,18,20 The remitting-relapsing
type is reported to be more common in younger patients as our
patient, and it has been shown that these patients respond well to
steroids and have a better prognosis. On the other hand, the
progressive type is seen more commonly in older patients, and
clinical ﬁndings resemble those seen in Creutzfeldt–Jakob disease,
and it is more likely to be partially or poorly responsive to steroids.
The latter presentation clinically must be ruled out for Creutzfeldt–
Jakob disease.
This patient’s complete and rapid response to plasmapheresis
was dramatic. The exclusion of infection especially given the fever
on presentation, the review of outside records showing a history of
HE, the early trial of high dose of steroids (e.g., methylpredni-
sonlone 1 g/d for 3–5 days), and lastly the addition of plasmaphe-
resis yielded dramatic improvement. The rapidity which this was
done also shortened his hospitalization and minimized nosocomial
complications. Including HE in the differential diagnosis of patients
with acute encephalopathy is important since this rare illness is
often fully reversible with appropriate therapy that includes
steroids and plasmapheresis.
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